Benchmark has reaffirmed its Buy rating on Abbott Laboratories (NYSE: ABT), keeping the price target unchanged at $120 per share. The decision comes as the US healthcare giant continues to benefit from robust sales in its medical devices and diagnostics divisions, which have helped offset currency headwinds in international markets.
Abbott shares traded broadly flat in pre-market activity on Friday, hovering around the $108 mark. The stock has gained approximately 8% so far this year, outperforming the broader S&P 500 healthcare sector, which is up just 3% over the same period. The company's diversified portfolio, spanning nutrition, diagnostics, medical devices, and established pharmaceuticals, provides a buffer against regional economic slowdowns, analysts note.
For UK investors holding US equities through pension funds or ISAs, the reaffirmed rating signals continued confidence in Abbott's ability to generate steady returns. The company's exposure to emerging markets, particularly in Asia and Latin America, offers growth potential that may appeal to those seeking international diversification. However, currency fluctuations remain a risk, as a stronger dollar can weigh on overseas earnings when converted back to sterling.
The broader healthcare sector has been under pressure this year due to regulatory uncertainties in the US and pricing concerns in Europe. Nonetheless, Abbott's focus on high-margin medical devices—such as its FreeStyle Libre glucose monitoring system—has helped it maintain margins above industry averages. Analysts at Benchmark expect the company to report second-quarter earnings in line with consensus estimates, with revenue growth driven by sustained demand for diagnostics and cardiovascular products.
While the $120 target implies an upside of roughly 11% from current levels, investors should be aware that the stock's valuation remains elevated relative to historical averages. Any negative surprises in upcoming earnings or a broader market downturn could delay the path to that target. As always, individual investment decisions should be based on personal financial circumstances and risk tolerance.